554 results match your criteria bnt162b2 vaccine

Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD IgG and Neutralizing Antibodies.

Transplantation 2021 Jul 6. Epub 2021 Jul 6.

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Background: Data about SARS-CoV-2 vaccines efficacy in renal transplant recipients (RTR) is lacking.

Methods: To reveal predictors for humoral response to BNT162b2 vaccine among RTR, patients were divided to positive (N=42) and negative (N=78) response groups based on receptor-binding domain (RBD) IgG >= 1.1 and neutralizing antibodies (NA) >= 16 dilution versus RBD IgG < 1. Read More

View Article and Full-Text PDF

Impact of SARS-CoV-2 variant-associated RBD mutations on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination.

Clin Infect Dis 2021 Jul 26. Epub 2021 Jul 26.

State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.

Background: Several SARS-CoV-2 lineages with mutations at the spike protein receptor binding domain (RBD) have reduced susceptibility to antibody neutralization, and have been classified as Variants of Concern (VOCs) or Variants of Interest (VOIs). Here, we systematically compared the neutralization susceptibility and RBD binding of different VOCs/VOIs, including B.1. Read More

View Article and Full-Text PDF

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape.

Front Immunol 2021 7;12:679344. Epub 2021 Jul 7.

Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, Gangwon-do, South Korea.

Recently, mRNA vaccines have become a significant type of therapeutic and have created new fields in the biopharmaceutical industry. mRNA vaccines are promising next-generation vaccines that have introduced a new age in vaccinology. The recent approval of two COVID-19 mRNA vaccines (mRNA-1273 and BNT162b2) has accelerated mRNA vaccine technology and boosted the pharmaceutical and biotechnology industry. Read More

View Article and Full-Text PDF

Humoral immune responses during SARS-CoV-2 mRNA vaccine administration in seropositive and seronegative individuals.

BMC Med 2021 07 26;19(1):169. Epub 2021 Jul 26.

Genomic Medicine Center, Children's Mercy Research Institute, Children's Mercy Kansas City, Kansas City, MO, 64108, USA.

Background: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by infection with the SARS-CoV-2 virus. Currently, there are three approved vaccines against SARS-CoV-2 in the USA, including two based on messenger RNA (mRNA) technology that has demonstrated high vaccine efficacy. We sought to characterize humoral immune responses, at high resolution, during immunization with the BNT162b2 (Pfizer-BioNTech) vaccine in individuals with or without prior history of natural SARS-CoV-2 infection. Read More

View Article and Full-Text PDF

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine.

Am J Case Rep 2021 Jul 25;22:e933003. Epub 2021 Jul 25.

BronxCare Center for Travel Medicine, Bronx Care Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.

BACKGROUND It is unknown if the efficacy of the coronavirus disease-19 (COVID-19) vaccine is affected by the co-administration of other vaccines. The Centers for Disease Control and Prevention (CDC) has shifted their recommendations recently, allowing for the co-administration of the currently available COVID-19 vaccines with other vaccines. This is based on the experience with non-COVID-19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone. Read More

View Article and Full-Text PDF

Active Covid-19 infection and transmission after the first dose of the BNT162b2 mRNA vaccination in Saudi Arabia: A case report.

J Infect Public Health 2021 Aug 13;14(8):1123-1125. Epub 2021 Jul 13.

Department of Medical Microbiology and Immunology, Taibah University, Madinah, Saudi Arabia; Department of Surgery and Cancer, Imperial College London, London, United Kingdom. Electronic address:

A 47-year-old non-smoker male who has received the first dose of the BNT162b2 mRNA Covid-19 vaccine in Saudi Arabia. At day 3 post-vaccination, he tested negative for Covid-19 and travelled to Egypt. On day 12 he developed runny nose, body ache and fever, and he reportedly tested (PCR) negative for Covid-19 Upon his return to Saudi on day 15, his symptoms have worsened and he presented to the Emergency Department, at which he tested positive for Covid-19. Read More

View Article and Full-Text PDF


Mult Scler Relat Disord 2021 Jul 15;54:103150. Epub 2021 Jul 15.

Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Visegradska 26A, 11000 Belgrade, Serbia.

Background: It has been generally accepted that people with MS (PwMS) should be vaccinated against COVID-19. The aim of our investigation was to evaluate the humoral response to natural SARS-CoV-2 infection and to two COVID-19 vaccines (BNT162b2 Pfizer-BioNTech and Beijing/Sinopharm BBIBP-CorV) in our cohort of PwMS under high efficacy disease modifying therapies (DMTs), cladribine and alemtuzumab.

Methods: Twenty two PwMS treated at the Clinic of Neurology, in Belgrade, who developed COVID-19 and/or were vaccinated against SARS-CoV-2, during treatment with cladribine and alemtuzumab, were included. Read More

View Article and Full-Text PDF

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals.

J Infect Public Health 2021 Aug 17;14(8):1120-1122. Epub 2021 Jul 17.

Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.

Great expectations are placed in vaccines against COVID-19 to control the pandemic. We reviewed the antibody titres in a cohort of healthcare workers (HCWs) vaccinated with BNT162b2 to assess the influence of a previous infection on them. We stratified the results according to the individual history of nasopharyngeal swab (NPS) and symptoms. Read More

View Article and Full-Text PDF

Post-SARS-CoV-2-vaccination Cerebral Venous Sinus Thrombosis: an analysis of cases notified to the European Medicines Agency.

Eur J Neurol 2021 Jul 22. Epub 2021 Jul 22.

Department of Neurosciences and Mental Health, Neurology Service, Hospital de Santa Maria/CHULN, University of Lisbon, Portugal.

Background: Cerebral venous sinus thrombosis (CVST) has been described after vaccination against SARS-CoV-2. We report clinical characteristics of 213 post-vaccination CVST cases notified to the European Medicines Agency (EMA).

Methods: Data on Adverse Drug Reactions after SARS-CoV-2 vaccination notified until 8 April 2021 under the Medical Dictionary for Regulatory Activities Term 'Central nervous system vascular disorders' were obtained from the EudraVigilance database. Read More

View Article and Full-Text PDF

The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living with HIV.

Clin Infect Dis 2021 Jul 22. Epub 2021 Jul 22.

Department of Medicine, Johns Hopkins Medicine, Baltimore, MD, USA.

Previous studies have shown that certain vaccines induce suboptimal responses in people living with HIV (PLWH). However, responses to SARS-CoV-2 vaccines have not been fully characterized in these patients. Here we show that the BNT162b2 vaccine induces robust immune responses comparable to responses in healthy donors. Read More

View Article and Full-Text PDF

Induction and exacerbation of subacute cutaneous lupus erythematosus following messenger-RNA or adenoviral-vector based SARS-CoV-2 vaccination.

Clin Exp Dermatol 2021 Jul 22. Epub 2021 Jul 22.

Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Hospital Oberhausen, University Witten, Herdecke, Germany.

Accumulating evidence exists that COVID-19 vaccines might induce or exacerbate autoimmune rheumatic diseases. Currently available COVID-19 vaccines include messenger-RNA (mRNA) and recombinant adenoviral (AdV) vector vaccines, both encoding SARS-CoV-2 spike protein production as the primary target for neutralizing antibodies. We herein report a case of subacute cutaneous lupus erythematosus (SCLE) following mRNA vaccination with BNT162b2, and summarize the current literature on cutaneous lupus erythematosus occurring after COVID-19 vaccination. Read More

View Article and Full-Text PDF

Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.

Nat Microbiol 2021 Jul 21. Epub 2021 Jul 21.

Nuffield Department of Medicine, University of Oxford, Oxford, UK.

We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, seroconversion rates and quantitative antibody levels after a single dose were lower in older individuals, especially in those aged >60 years. Two vaccine doses achieved high responses across all ages. Antibody levels increased more slowly and to lower levels with a single dose of ChAdOx1 compared with a single dose of BNT162b2, but waned following a single dose of BNT162b2 in older individuals. Read More

View Article and Full-Text PDF


Int J Infect Dis 2021 Jul 18. Epub 2021 Jul 18.

Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy; Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy; Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milano, Italy.

Background Uveitis is a vision-threatening inflammation and is considered an ophthalmic emergency. It is generally referred to systemic diseases, such as autoimmune conditions, infections, to ocular trauma or can occur as an isolated disorder. In the past decades, several cases of vaccine-associated uveitis have been described, with HBV-vaccine being the leading cause. Read More

View Article and Full-Text PDF

Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021.

Emerg Infect Dis 2021 Jul 21;27(10). Epub 2021 Jul 21.

An outbreak of severe acute respiratory syndrome coronavirus 2 caused by the Gamma variant of concern infected 24/44 (55%) employees of a gold mine in French Guiana (87% symptomatic, no severe forms). The attack rate was 60% (15/25) among fully vaccinated miners and 75% (3/4) among unvaccinated miners without a history of infection. Read More

View Article and Full-Text PDF

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.

N Engl J Med 2021 Jul 21. Epub 2021 Jul 21.

From Public Health England (J.L.B., N.A., C.G., E.G., R.S., S.T., J.S., E.T., N.G., G.D., R.M., C.N.J.C., G.A., M.E., M.Z., K.E.B., S.H., M.C., M.R.), the National Institute of Health Research (NIHR) Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine (J.L.B., N.A., C.N.J.C., G.A., K.E.B., M.R.), the NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London (J.L.B., M.Z.), and Guy's and St. Thomas' Hospital NHS Trust (M.C.), London, and Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford (S.H.) - all in the United Kingdom.

Background: The B.1.617. Read More

View Article and Full-Text PDF

Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel.

Eur J Neurol 2021 Jul 21. Epub 2021 Jul 21.

Department of Neurology, Rabin Medical Center, Petah Tikva, Israel.

Background And Purpose: Although the COVID-19 vaccines are currently recommended for people with multiple sclerosis (MS), the fact that they were not specifically tested in people with MS raises uncertainty regarding their safety in this population. The purpose of this study was to report real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients.

Methods: An anonymous survey was distributed to 425 MS patients. Read More

View Article and Full-Text PDF

COVID-19 vaccine-associated cerebral venous thrombosis in Germany.

Ann Neurol 2021 Jul 19. Epub 2021 Jul 19.

Institute of Public Health, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.

Objective: We aimed to estimate the incidence of cerebral sinus and venous thrombosis (CVT) within one month from first-dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination with BNT162b2, ChAdOx1, and mRNA-1273, in Germany.

Methods: A web-based questionnaire was e-mailed to all Departments of Neurology. We asked to report cases of CVT within one month of a COVID-19 vaccination. Read More

View Article and Full-Text PDF

Potency of BNT162b2 and mRNA-1273 vaccine-induced neutralizing antibodies against severe acute respiratory syndrome-CoV-2 variants of concern: A systematic review of in vitro studies.

Rev Med Virol 2021 Jul 19:e2277. Epub 2021 Jul 19.

Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

BNT162b2 and mRNA-1273 are two types of mRNA-based vaccine platforms that have received emergency use authorization. The emergence of novel severe acute respiratory syndrome (SARS-CoV-2) variants has raised concerns of reduced sensitivity to neutralization by their elicited antibodies. We aimed to systematically review the most recent in vitro studies evaluating the effectiveness of BNT162b2 and mRNA-1273 induced neutralizing antibodies against SARS-CoV-2 variants of concern. Read More

View Article and Full-Text PDF

Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort-19 study.

Allergy 2021 Jul 19. Epub 2021 Jul 19.

Clinical research and epidemiology unit, University hospital, Montpellier, France.

Background: The humoral immune response following COVID-19 vaccination in nursing home residents is poorly known. A longitudinal study compared levels of IgG antibodies against the spike protein (S-RBD IgG) (S-RDB protein IgG) after one and two BNT162b2/Pfizer jabs in residents with and without prior COVID-19.

Methods: In 22 French nursing homes, COVID-19 was diagnosed with real-time reverse-transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2. Read More

View Article and Full-Text PDF

A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination.

Am J Case Rep 2021 Jul 21;22:e931478. Epub 2021 Jul 21.

Department of Family Medicine and Public Health Sciences, Wayne State University, Detroit, MI, USA.

BACKGROUND Immune thrombocytopenic purpura (ITP) is an immune response that destroys platelets and increases the risk of bleeding, which can range from bruising to intracranial hemorrhage. ITP is a known complication of coronavirus disease 2019 (COVID-19). In the first studies of the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine, there were no reports of ITP and the incidence of serious adverse events (AEs) was low overall. Read More

View Article and Full-Text PDF

The ROMANOV study found impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis.

Kidney Int 2021 Jul 17. Epub 2021 Jul 17.

CIRI, INSERM U1111, Université Claude Bernard Lyon I, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Univ. Lyon, 21 avenue Tony Garnier, 69007 Lyon, France; Claude Bernard University (Lyon 1), 43 boulevard du 11 Novembre 1918, 69622 Villeurbanne France.; Hospices Civils de Lyon, Edouard Herriot Hospital, Department of Transplantation, Nephrology and Clinical Immunology, 5, place d'Arsonval, 69003 Lyon, France. Electronic address:

Patients on maintenance hemodialysis (MHD), which are at high risk of infection by SARS-CoV-2 virus and death due to COVID-19, have been prioritized for vaccination. However, because they were excluded from pivotal studies and have weakened immune responses, it is not known whether these patients are protected after the "standard" two doses of mRNA vaccines. To answer this, anti-spike receptor binding domain (RBD) IgG and interferon gamma-producing CD4 and CD8 specific-T cells were measured in the circulation 10-14 days after the second injection of BNT162b2 vaccine in 106 patients receiving MHD (14 with history of COVID-19) and compared to 30 healthy volunteers (four with history of COVID-19). Read More

View Article and Full-Text PDF

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.

Clin Exp Med 2021 Jul 20. Epub 2021 Jul 20.

Department of Clinical Therapeutics, School of Medicine, Alexandra General Hospital, National and Kapodistrian University of Athens, 80 Vas. Sofias Avenue, 11528, Athens, Greece.

Vaccination against SARS-CoV-2 is considered as the most important preventive strategy against COVID-19, but its efficacy in patients with hematological malignancies is largely unknown. We investigated the development of neutralizing antibodies (NAbs) against SARS-CoV-2 in patients with Waldenstrom Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). After the first dose of the vaccine, on D22, WM/CLL/NHL patients had lower NAb titers compared to controls: the median NAb inhibition titer was 17% (range 0-91%, IQR 8-27%) for WM/CLL/NHL patients versus 32% (range 2-98%, IQR 19-48%) for controls (P < 0. Read More

View Article and Full-Text PDF

Prevention of COVID-19 by mRNA-based vaccines within the general population of California.

Clin Infect Dis 2021 Jul 20. Epub 2021 Jul 20.

Division of Epidemiology and Biostatistics, School of Public Health, University of California at Berkeley, Berkeley, California, United States.

Background: Estimates of COVID-19 vaccine effectiveness under real-world conditions, and understanding of barriers to uptake, are necessary to inform vaccine rollout.

Methods: We enrolled cases (testing positive) and controls (testing negative) from among the population whose SARS-CoV-2 molecular diagnostic test results from 24 February-29 April 2021 were reported to the California Department of Public Health. Participants were matched on age, sex, and geographic region. Read More

View Article and Full-Text PDF

Autoimmune phenomena following SARS-CoV-2 vaccination.

Int Immunopharmacol 2021 Jul 10;99:107970. Epub 2021 Jul 10.

Department of Medicine, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel; Rheumatology Unit, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel. Electronic address:

Vaccines represent an attractive possible solution to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Widespread vaccine distribution has yet to occur in most countries, partially due to public concerns regarding possible side effects. While studies indicate the vaccine is exceptionally safe, rare systemic side effects remain possible. Read More

View Article and Full-Text PDF

Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals.

EClinicalMedicine 2021 Aug 13;38:101018. Epub 2021 Jul 13.

Department of Anthropology and Institute for Policy Research, Northwestern University, 1810 Hinman Avenue, Evanston, IL 60208 USA.

Background: Recent reports have suggested that among individuals previously infected with SARS-CoV-2, a single mRNA vaccine dose is sufficient to elicit high levels of immunity.

Methods: We compared anti-SARS-CoV-2 spike receptor binding domain (RBD) IgG antibody concentrations and antibody-mediated neutralization of spike-angiotensin-converting enzyme (ACE2) receptor binding following vaccination of non-hospitalized participants by sero-status and acute virus diagnosis history. Participants were analysed before and after mRNA vaccination (BNT162b2/Pfizer or mRNA-1273/Moderna) in a community-based, home-collected, longitudinal serosurvey in the Chicago area (USA); none reported hospitalization for COVID-19. Read More

View Article and Full-Text PDF

Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis.

Front Immunol 2021 30;12:690698. Epub 2021 Jun 30.

Department of Nephrology and Intensive Care, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Patients with kidney failure have notoriously weak responses to common vaccines. Thus, immunogenicity of novel SARS-CoV-2 vaccines might be impaired in this group. To determine immunogenicity of SARS-CoV-2 vaccination in patients with chronic dialysis, we analyzed the humoral and T-cell response after two doses of mRNA vaccine Tozinameran (BNT162b2 BioNTech/Pfizer). Read More

View Article and Full-Text PDF

Safety and Tolerability of SARS-CoV-2 Emergency-Use Authorized Vaccines Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Transplant Cell Ther 2021 Jul 15. Epub 2021 Jul 15.

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

Background: The safety and efficacy of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emergency-use authorized (EUA) vaccines has been confirmed in general population. However, there is no data on its safety/tolerability or efficacy in recipients of allogeneic hematopoietic stem cell transplant (HCT).

Objectives: We performed this study to identify the incidence of adverse events following SARS-CoV2 EUA vaccines and the incidence of new onset GVHD or worsening of existing GVHD after EUA vaccine administration and the incidence SAR-CoV2 positivity in vaccinated HCT patients. Read More

View Article and Full-Text PDF